PIK3CA and breast cancer: Targeting single PI3K isoforms has, therefore, emerged as a safer therapeutic option because isoform-specific PI3K inhibitors are better tolerated by patients and can also be more easily combined with additional targeted therapies as is currently being tested with hormone therapies and cell cycle checkpoint inhibitors for the treatment of multiple types of breast cancer [50].